Robert Glanzman
Net worth: 4 490 $ as of 2024-03-30
Profile
Robert Glanzman worked as a Senior Medical Director at Pfizer AG, Director-Clinical Research at Purdue Pharmaceuticals LP, Vice President-Clinical Development at Nektar Therapeutics, and Assistant Clinical Professor at the University of Michigan.
He also served as the Chief Medical Officer at GeNeuro SA (Switzerland) from 2015 to 2019 and is currently the Chief Medical Officer at Clene, Inc. Dr. Glanzman earned his doctorate degree from Wake Forest School of Medicine in 1987 and his undergraduate degree from The University of North Carolina at Charlotte in 1982.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CLENE INC
0.01% | 2023-03-12 | 10,564 ( 0.01% ) | 4 490 $ | 2024-03-30 |
Former positions of Robert Glanzman
| Companies | Position | End |
|---|---|---|
| CLENE INC. | Chief Tech/Sci/R&D Officer | 2023-03-31 |
| GENEURO SA | Chief Tech/Sci/R&D Officer | 2019-06-29 |
| University of Michigan | Corporate Officer/Principal | - |
| Pfizer AG | Chief Tech/Sci/R&D Officer | - |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | - |
Training of Robert Glanzman
| Wake Forest School of Medicine | Doctorate Degree |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| GENEURO SA | Health Technology |
| CLENE INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Pfizer AG | |
Purdue Pharmaceuticals LP
 Purdue Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Purdue Pharmaceuticals LP is a physician-founded and physician-led company that develops, manufactures, and markets medications and consumer health products. Purdue Pharmaceuticals is based in Wilson, NC and offers a diverse product line. The private company is committed to supporting collaborations to drive innovations in patient care while addressing the opioid addiction crisis. | Health Technology |
- Stock Market
- Insiders
- Robert Glanzman
